Baseret på klinisk erfaring, kan en stigning i Kaletra dosis til 533/ 133 mg (4 kapsler) to gange dagligt overvejes, når det gives sammen med nevirapin, særligt til patienter, der har en sandsynlig nedsat lopinavir følsomhed.
However, based on clinical experience, Kaletra dose increase to 533/ 133 mg (4 capsules) twice daily may be considered when co-administered with nevirapine, particularly for patients in whom reduced lopinavir susceptibility is likely.